REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RBC Cuts Price Target on Regeneron Pharmaceuticals to $647 From $658, Noting Risk to Eylea From Biosimilars; Sector Perform Kept

06/14/2022 | 07:26am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Regeneron Pharmaceuticals - NOVEL COSTIMULATORY BISPECIFIC ANTIBODY SHOWS ENCOURAGING A..
AQ
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
08/03WALL STREET STOCK EXCHANGE : A couple of hopes dashed
MS
08/03REGENERON PHARMACEUTICALS : Corporate Presentation August 2022
PU
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 799 M - -
Net income 2022 3 807 M - -
Net cash 2022 4 839 M - -
P/E ratio 2022 18,3x
Yield 2022 -
Capitalization 67 420 M 67 420 M -
EV / Sales 2022 5,30x
EV / Sales 2023 4,39x
Nbr of Employees 10 715
Free-Float 80,5%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 630,63 $
Average target price 676,32 $
Spread / Average Target 7,24%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375
GENMAB A/S-2.51%22 993